Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/II HER2+ breast cancer.

被引：0
|
作者：
Limentani, S
Dorval, T
White, S
Curigliano, G
Campone, M
Disis, N
Piccart, M
Cheever, M
Gérard, C
Brichard, VG
Gauducheau, R
机构：
[1] Carolinas Oncol, Charlotte, NC USA
[2] Curie, Paris, France
[3] Austin MC, Heidelberg, Vic, Australia
[4] IEO, Milan, Italy
[5] Univ Washington, Seattle, WA 98195 USA
[6] Bordet, Brussels, Belgium
[7] Corixa Corp, Seattle, WA USA
[8] GlaxoSmithKline Biol, Rixensart, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：170S / 170S
页数：1
相关论文
共 50 条
  • [1] Phase I/II study of adoptive T-cell therapy following in vivo priming with a HER2/neu vaccine in patients with advanced-stage HER2+ breast cancer.
    Disis, Mary L.
    Coveler, Andrew L.
    Higgins, Doreen
    D'Amico, Leonard A.
    Morishima, Chihiro
    Waisman, James Ross
    Reichow, Jessica
    Childs, Jennifer
    Dang, Yushe
    Salazar, Lupe G.
    Marzbani, Edmond
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Phase I/II study of neoadjuvant eribulin mesylate, carboplatin, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer.
    Schwartzberg, Lee Steven
    Tauer, Kurt W.
    Hermann, Robert C.
    Nikolinakos, Petros G.
    Houts, Arthur C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Phase I/II study of neoadjuvant carboplatin, eribulin mesylate, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer.
    Schwartzberg, Lee Steven
    Tauer, Kurt W.
    Hermann, Robert C.
    Nikolinakos, Petros G.
    Houts, Arthur C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2 D breast cancer
    Grinshpun, A.
    Ren, S.
    Graham, N.
    Demeo, M. K.
    Wrabel, E.
    Carter, J.
    Tayob, N.
    Pereslete, A.
    Hamilton, E.
    Juric, D.
    Mayer, E. L.
    Tolaney, S. M.
    Krop, I. E.
    Metzger, O.
    ESMO OPEN, 2024, 9 (06)
  • [5] A phase I trial of the safety and immunogenicity of a DNA-based vaccine encoding the HER2/neu (HER2) intracellular domain in subjects with HER2+breast cancer.
    Disis, Mary L.
    Coveler, Andrew L.
    Higgins, Doreen
    Fintak, Patricia
    Waisman, James Ross
    Reichow, Jessica
    Slota, Meredith
    Childs, Jennifer
    Dang, Yushe
    Salazar, Lupe G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases
    Metzger Filho, O.
    Leone, J. P.
    Li, T.
    Tan-Wasielewski, Z.
    Trippa, L.
    Barry, W. T.
    Younger, J.
    Lawler, E.
    Walker, L.
    Freedman, R. A.
    Tolaney, S. M.
    Krop, I
    Winer, E. P.
    Lin, N. U.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1231 - 1239
  • [7] A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer.
    Wong, ZW
    Isaacs, C
    Harris, L
    Ellis, MJ
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S106 - S107
  • [8] Phase II trial of lapatinib for brain metastases in patients with HER2+breast cancer.
    Lin, N. U.
    Carey, L. A.
    Liu, M. C.
    Younger, J.
    Come, S. E.
    Bullitt, E.
    Van den Abbeele, A. D.
    Li, X.
    Hochberg, F. H.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 3S - 3S
  • [9] A phase I dose-escalation trial of alpha-tocopheryloxyacetic acid and concurrent trastuzumab in patients with treatment refractory HER2+metastatic breast cancer.
    Gwin, William R.
    Childs, Jennifer
    Higgins, Doreen
    Burton, Kellie Ann
    Kuano, Kristin
    Corulli, Lauren
    Dai, James
    Akporiaye, Emmanuel T.
    Disis, Mary L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Phase Ib dose-escalation trial of the AKT inhibitor (AKTi) MK2206 in combination with paclitaxel (P) and trastuzumab (H) in patients (pts) with HER2-overexpressing (HER2+) cancer.
    Chien, Amy Jo
    Thach-Giao Truong
    Melisko, Michelle E.
    Moasser, Mark M.
    Kelley, Robin Katie
    Korn, Michael
    Ko, Andrew H.
    Pantoja, Norma
    Reinert, Anne
    Grabowsky, Jennifer A.
    Magbanua, Mark Jesus M.
    Rugo, Hope S.
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345